3G6 Stock Chart & Stats
€17.50
€0.40(2.20%)
At close: 4:00 PM EST
€17.50
€0.40(2.20%)
Day’s Range― - ―
52-Week Range€11.90 - €19.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€818.64M
Enterprise Value€127.86B
Total Cash (Recent Filing)€19.87B
Total Debt (Recent Filing)€5.17B
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 14, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-112.69
Shares Outstanding65,817,420
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)2.52
Price to Sales (P/S)4.71
P/FCF Ratio-46.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.37Price Target Upside16.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.29
Revenue Forecast (FY)€163.94M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthSustained TTM revenue growth of +76.5% indicates durable demand expansion and market traction. Over 2–6 months this revenue base supports scale, enables investment in R&D or commercialization, and gives management runway to restore profitability if cost discipline follows.
High Gross MarginsGross margins near 74% reflect strong product-level economics and pricing power. This structural margin buffer allows the company to absorb SG&A or R&D loads while still having a clear pathway to operating profitability as revenue scales or fixed costs are optimized.
Conservative Leverage / Sizable Equity BaseLow debt-to-equity (~0.10) and a ~¥50B equity base provide financial flexibility. This durable balance-sheet strength reduces near-term refinancing pressure, supports funding of operations or pipeline investments, and lowers bankruptcy risk while margins recover.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow (-¥2.5B / -¥2.9B TTM) forces reliance on reserves or external financing. Over the medium term this increases execution and dilution risk, constrains self-funding for growth or trials, and raises the probability of capital raises if losses persist.
Negative Profitability / Operating LossesA negative net margin (-8.5%) and recent operating losses signal that current revenue levels have not yet translated to sustainable profits. This undermines return generation and means management must either improve margins materially or fund losses, limiting shareholder value creation.
Balance-sheet Volatility & Past Higher LeverageHistorical balance-sheet volatility and prior periods of higher debt-to-equity show capital-structure sensitivity to operational swings. If adverse cash trends continue, the company may face higher borrowing costs or dilutive equity raises, weakening long-term financial stability.
GNI Group News
3G6 FAQ
What was GNI Group Ltd.’s price range in the past 12 months?
GNI Group Ltd. lowest stock price was €11.90 and its highest was €19.60 in the past 12 months.
What is GNI Group Ltd.’s market cap?
GNI Group Ltd.’s market cap is €818.64M.
When is GNI Group Ltd.’s upcoming earnings report date?
GNI Group Ltd.’s upcoming earnings report date is Aug 14, 2026 which is in 14 days.
How were GNI Group Ltd.’s earnings last quarter?
GNI Group Ltd. released its earnings results on May 15, 2026. The company reported -€0.205 earnings per share for the quarter, missing the consensus estimate of -€0.015 by -€0.19.
Is GNI Group Ltd. overvalued?
According to Wall Street analysts GNI Group Ltd.’s price is currently Undervalued.
Does GNI Group Ltd. pay dividends?
GNI Group Ltd. does not currently pay dividends.
What is GNI Group Ltd.’s EPS estimate?
GNI Group Ltd.’s EPS estimate is -0.33.
How many shares outstanding does GNI Group Ltd. have?
GNI Group Ltd. has 65,817,420 shares outstanding.
What happened to GNI Group Ltd.’s price movement after its last earnings report?
GNI Group Ltd. reported an EPS of -€0.205 in its last earnings report, missing expectations of -€0.015. Following the earnings report the stock price went down -3.145%.
Which hedge fund is a major shareholder of GNI Group Ltd.?
Currently, no hedge funds are holding shares in DE:3G6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
3G6 Stock 12 Month Forecast
Average Price Target
€20.37
▲(16.41% Upside)